“`html
Kewaunee Scientific Corporation (KEQU) reported a 47.1% increase in shares following its fourth-quarter fiscal results for 2025, significantly outperforming the S&P 500’s 6.1% growth in the same period. The stock rose 46% over the past month, compared to a 14.5% gain for the S&P 500.
Financial Performance
For the fourth quarter ending April 30, 2025, Kewaunee reported net sales of $77.1 million, up 36.1% from $56.7 million the previous year. Adjusted diluted earnings per share (EPS) increased to $1.95, a 25.8% rise from $1.55, while adjusted net earnings rose 26.6% to $5.8 million. For fiscal 2025, total net sales reached $240.5 million, representing an 18% increase from $203.8 million in 2024.
Segment Insights
The domestic segment saw sales soar by 54.7% to $55.5 million, significantly benefiting from the acquisition of Nu Aire, while international sales grew by 3.9% to $21.7 million. However, the corporate segment reported an adjusted EBITDA loss of $1.4 million, highlighting integration costs associated with the Nu Aire acquisition.
“`